STADA Arzneimittel Aktiengesellschaft Stock Price, News & Analysis (ETR:SAZ) €80.40 0.00 (0.00%) (As of 11/27/2018) Add Compare Share Share Today's Range€79.56▼€80.9850-Day Range€80.40▼€80.4052-Week Range€53.41▼€80.98Volume92,068 shsAverage Volume51,761 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A About STADA Arzneimittel Aktiengesellschaft Stock (ETR:SAZ)STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.Read More SAZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAZ Stock News HeadlinesNovember 5, 2023 | seekingalpha.comBayerische Motoren Werke Aktiengesellschaft 2023 Q3 - Results - Earnings Call PresentationApril 9, 2023 | finance.yahoo.comBasler Aktiengesellschaft (ETR:BSL) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportNovember 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comApril 6, 2023 | finanznachrichten.dePTA-HV: Deutsche Real Estate Aktiengesellschaft: -3-April 6, 2023 | reuters.comSTADA Arzneimittel AGFebruary 25, 2023 | msn.comHOCHTIEF Aktiengesellschaft Non-GAAP EPS of €1.68, revenue of €7.09BFebruary 22, 2023 | finanznachrichten.deAktuelle Empfehlungen zur STADA ARZNEIMITTELDecember 1, 2022 | finance.yahoo.comIs There An Opportunity With InVision Aktiengesellschaft's (ETR:IVX) 49% Undervaluation?November 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 30, 2022 | seekingalpha.comOMV Aktiengesellschaft (OMVJF) Q3 2022 Earnings Call TranscriptOctober 30, 2022 | finanznachrichten.deEQS-News: Lloyd Fonds Aktiengesellschaft: Barkapitalerhöhung erfolgreich umgesetztSeptember 14, 2022 | thestreet.comStada Arzneimittel Shares Tumble After $6 Billion Civen/Bain Takeover CollapseFebruary 10, 2021 | marketwatch.comGeneric Drugs Market Size Worth Around US$ 675.2 Bn by 2030February 10, 2021 | benzinga.comGlobal Erythropoietin Market Report (2020 to 2030) - COVID-19 Growth and ChangeFebruary 10, 2021 | apnews.comWorldwide Industry for Erythropoietin to 2030 - Featuring Amgen, Roche and Pfizer Among Others - ResearchAndMarkets.comFebruary 3, 2021 | marketwatch.comGlobal Parkinson's Disease Drug Market 2020 Industry Analysis, Size, Share, Growth, Trend and Forecast to 2025February 2, 2021 | marketwatch.comGlobal Generic Drugs Market : Regional Industry Segmentation, Analysis by Production, Consumption, Revenue and Growth Rate by 2027January 12, 2021 | marketwatch.comBiosimilars Market Size, Key Regions, Development Status, CAGR Value, Total Revenues, Future Outlook, Opportunities and Drivers, Forecast to 2023December 29, 2020 | apnews.comRecombinant Non-Glycosylated Proteins Biosimilars Market 2020 Size, Marketing Channels, Major Industry Participants – SandozPfizerDecember 21, 2020 | benzinga.comErythropoietin (EPO) Global Market Report 2020-30: COVID-19 Growth and ChangeDecember 10, 2020 | markets.businessinsider.comSTADA agreement extended for the Nordic RegionDecember 3, 2020 | marketwatch.comGlobal Opipramol Market 2020 Key Players Data, Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2025December 3, 2020 | marketwatch.comGlobal Opipramol Market Size Study with COVID-19 Impact 2020 Research Strategies and Forecast to 2025November 24, 2020 | marketwatch.comGlobal Bio Similars/Subsequent Entry Biologic Market 2020 Key Drivers and Challenges, Opportunities and Forecast Insights by 2026November 17, 2020 | news.yahoo.comBiosimilars Market - Global Opportunity Analysis and Industry Forecast up to 2026 - ResearchAndMarkets.comNovember 12, 2020 | news.yahoo.comGlobal Biosimilars Market Report 2020November 11, 2020 | marketwatch.comGlobal Parkinson's Disease Therapeutics Market 2020 Technological Strategies, Business Advancements and Top-Vendor Landscape to 2026See More Headlines Receive SAZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for STADA Arzneimittel Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolETR:SAZ CUSIPN/A CIKN/A Webwww.stada.de Phone+49-6101-6030FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Mark Burgess Keatley MBA (Age 61)MA, MPhil, CFO & Member of Exec. Board Mr. Peter Goldschmidt (Age 54)Chairman of the Exec. Board & CEO Mr. Miguel Pagan Fernandez (Age 53)CTO & Member of Exec. Board Mr. Sebastian Kramer-Bach (Age 43)Exec. VP of Corp. Communication Ms. Kay ReubeltDirector of Investor RelationsKey CompetitorsTeva Pharmaceutical IndustriesFRA:TEVEssilor International Société AnonymeEPA:EIFielmann GroupFRA:FIEFresenius SE & Co. KGaAFRA:FREGenfitEPA:GNFTView All Competitors SAZ Stock Analysis - Frequently Asked Questions How have SAZ shares performed in 2023? STADA Arzneimittel Aktiengesellschaft's stock was trading at €80.40 on January 1st, 2023. Since then, SAZ shares have increased by 0.0% and is now trading at €80.40. View the best growth stocks for 2023 here. What other stocks do shareholders of STADA Arzneimittel Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some companies that other STADA Arzneimittel Aktiengesellschaft investors own include ProSiebenSat.1 Media (PSM), Renault (RNO), Sarepta Therapeutics (SRPT), Volkswagen Aktiengesellschaft (VLKAY), Volkswagen (VOW3), ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), Andersons (ANDE) and ANI Pharmaceuticals (ANIP). This page (ETR:SAZ) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding STADA Arzneimittel Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.